SCHEMBL6235409

SCHEMBL6235409

CN1C(=O)NC(=O)C1(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162703 0.72 ATAD2 (0.33)
SCHEMBL6579528 0.72 ATAD2 (0.33)
SCHEMBL9775551 0.70 ATAD2 (0.32)
SCHEMBL23962148 0.68
SCHEMBL4621098 0.68
SCHEMBL1396164 0.65
SCHEMBL542452 0.65 LMNA (0.36)
SCHEMBL1362238 0.64
SCHEMBL7955151 0.63 ALDH1A1 (0.31)
SCHEMBL6357420 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0160618-A1 Hydantoin derivatives and pharmaceutical compositions containing them NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1985-11-06 EP claimed
EP-3639821-B1 CARCINOGENESIS INHIBITOR NAT CANCER CT (JP) 2024-08-28 EP disclosed
CN-110740729-B Carcinogenesis inhibitor 国立研究开发法人国立癌症研究中心 2023-05-16 CN disclosed
US-11464762-B2 Carcinogenesis inhibitor NATIONAL CANCER CENTER (JP) 2022-10-11 US disclosed
US-20200276163-A1 CARCINOGENESIS INHIBITOR NATIONAL CANCER CENTER (JP) 2020-09-03 US disclosed
EP-3639821-A1 CARCINOGENESIS INHIBITOR National Cancer Center (JP) 2020-04-22 EP disclosed
CN-110740729-A Carcinogenesis inhibitor 国立研究开发法人国立癌症研究中心 2020-01-31 CN disclosed
EP-1243261-B1 Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia NIPPON ZOKI PHARMACEUTICAL CO (JP) 2005-04-27 EP disclosed
EP-1018339-B1 Use of hydantoin derivatives for the preparation of a medicament for the treatment of intractable vasculitis. NIPPON ZOKI PHARMACEUTICAL CO (JP) 2003-05-02 EP disclosed
US-20020147228-A1 AGENT FOR HYPOALBUMINAEMIA NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2002-10-10 US disclosed
EP-1243261-A1 Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2002-09-25 EP disclosed
US-6451831-B1 TREATMENT WITH HYDANTOIN DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2002-09-17 US disclosed
US-6251929-B1 ADMINISTERING TO A PATIENT A HYDANTOIN DERIVATIVES AND SALTS AS THERAPEUTIC AND PREVENTIVE AGENTS FOR INTRACTABLE VASCULITIS SUCH AS MALIGNANT RHEUMATOID ARTHRITIS(MRA), PERIARTERITIS NODOSA, WEGENER'S GRANULOMATOSIS ETC. NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) 2001-06-26 US disclosed
EP-0780125-B1 Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals NIPPON ZOKI PHARMACEUTICAL CO (JP) 2001-04-18 EP disclosed
US-6197806-B1 USING A HYDANTOIN DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2001-03-06 US disclosed
EP-1018339-A1 Therapeutic agent for intractable vasculitis NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2000-07-12 EP disclosed
EP-0780125-A2 Pharmaceutical composition containing a hydantoin derivative and use of said derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1997-06-25 EP disclosed
EP-0160618-B1 HYDANTOIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1991-08-14 EP disclosed
US-4647574-A Hypoglycemic hydantoin derivatives NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1987-03-03 US disclosed
EP-0160618-A1 Hydantoin derivatives and pharmaceutical compositions containing them NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1985-11-06 EP disclosed